all report title image
  • Published On : May 2023
  • Code : CMI2933
  • Industry : Pharmaceutical
  • Pages : 178
  • Formats :

Global subcutaneous drug delivery market is estimated to be valued at US$ 11.88 billion in 2023 and is expected to exhibit a CAGR of 9.7% during the forecast period (2023-2030).

Analysts’ Views on Global Subcutaneous Drug Delivery Market:

Increasing convenience and safety for both patients and medical professionals offered by subcutaneous devices are major factors leading to the growth of the global subcutaneous drug delivery market. For instance, According to the National Health Institute (NIH), 2020, around 2 million healthcare professionals suffered from infectious diseases as a result of needlestick injuries. The retractable nature of prefilled syringes helps to overcome this problem, thereby acting as an ideal device to reduce the occurrence of needlestick injuries.

Figure 1. Global Subcutaneous Drug Delivery Market Share (%), By Usability, 2023

Subcutaneous Drug Delivery  | Coherent Market Insights

Global Subcutaneous Drug Delivery Market – Drivers

Adoption of inorganic growth strategies by key players

Increasing focus of manufacturers on the adoption of inorganic growth strategies such as collaboration and partnership, in order to strengthen their product portfolio of subcutaneous drug delivery systems is expected to drive the market growth over the forecast period. For instance, in March 2021, the collaboration between Eitan Medical device company, provides drug delivery devices and medical pumps and Stevanato Group, a glass container manufacturing company launched a wearable injection device for the simple and efficient subcutaneous administration of large-volume and high-viscosity medications that provide the interests of both patients and pharmaceutical companies.

CMI table icon

Subcutaneous Drug Delivery Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 11.88 Bn
Historical Data for: 2017 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 9.7% 2030 Value Projection: US$ 22.73 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Usability: Disposable, Reusable
  • By Disease Indication: Auto-immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, Allergy & Infectious Disorders, Ophthalmic Disorders, Others
  • By Delivery System: Prefilled Syringes, Autoinjector (Spring Type, Motorized Type, Wearable Type), Pen Injectors, Disposable (Reusable, Syringes (Injector)), Others(pump and etc.)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Becton Dickinson and Company., Novo Nordisk A/S, Johnson & Johnson, Novartis International AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG., Consort Medical plc LaVision Biotec GmbH, Eli Lilly and Company., Merck & Co., Inc, Insulet Corporation., West Pharmaceutical Services, Inc. Gerresheimer AG.

Growth Drivers:
  • Adoption of inorganic growth strategies by key players 
  • Increasing focus on preventing the needlestick injuries 
Restraints & Challenges:
  • Increasing number of product recalls

Increasing focus on preventing the needlestick injuries

Needlestick injuries with injection needles and lancing devices are a key concern of patients with diabetes. Insulin syringe needlestick injuries is a percutaneous wound injury caused by needle tips and can occur while using, handling, disassembling, or disposing of needles and syringes. Increasing awareness regarding safety and concern about needlestick injuries are major factors driving the growth of the subcutaneous drug delivery market.

Preference for safety injection devices is increasing among healthcare professionals and manufacturers, as these devices decrease the chances of needlestick injuries. For instance, the WHO recommended the use of safety syringes with sharp injury protection (SIP) in order to prevent needlestick injuries. Moreover, in May 2021, Innovative Neurons LLC, is a medical device company has announced its plan to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology), to decrease needlestick injuries.

Figure 2. Global Subcutaneous Drug Delivery Market Share (%), By Region, 2023

Subcutaneous Drug Delivery  | Coherent Market Insights

Global Subcutaneous Drug Delivery Market - Regional Analysis

Increasing product launches by market players is expected to drive the market growth. North America is expected to hold a dominant position in the market, owing to the large healthcare industry in the region. Market players are focused on launching new products in the region. According to the WHO (World Health Organization), over 16 billion injections are administered annually in transitional and developing countries the world over. For instance, in June 2021, Hindustan Syringes & Medical Devices company, launch single-use dispojekt safety needle to prevent injuries.

Global Subcutaneous Drug Delivery Market – Impact of Coronavirus (COVID-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 5 million infected individuals worldwide as of June 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. are being disrupted due to global lockdown while many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

The stockpiling of subcutaneous or oral formulations due to the lockdown may cause a spike in demand for certain products. According to an article published in the Center for Biosimilars (American Journal of Managed Care), on February 27, 2020, manufacturers such as Novartis AG who have manufacturing facilities in Austria, Europe, are particularly at risk on the supply side.

Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global subcutaneous drug delivery market during the forecast period

Global Subcutaneous Drug Delivery Market - Segmentation

Global Subcutaneous Drug Delivery market is segmented into Usability, Disease Indication, By Delivery System, By Distribution Channel, and By Region.

Based on Usability, the market is segmented into disposable and reusable. Out of which, the reusable segment dominated the global subcutaneous drug delivery market during the forecast period. For instance, in May 2022, Jabil Inc., a medical device company, announced the launch of the Qfinity Autoinjector Platform. It is a reusable drug delivery system with wide application.

Based on Disease Indication, the market is segmented into auto-immune disorders, neurological disorders, oncology disorders, hormonal disorders, allergy & infectious disorders, ophthalmic disorders, and others. Out of which, the auto-immune disorder segment dominated the global subcutaneous drug delivery market. For instance, in November 2020, according to the autoimmune registry inc (ari), between 15 and 30 million people in the U.S. suffer from autoimmune disease. It mostly affects women between the ages of 20 and 40, making it the largest class of illnesses in the country.

Based on Delivery System, the market is segmented into prefilled syringes, auto injector, pen injectors, disposable, and others. Out of the which pen injector segment dominated to the global subcutaneous drug delivery market, For instance, on February 2, 2023, according to AstraZeneca ,British-Swedish multinational pharmaceutical and biotechnology company, has announced received approval from U.S FDA for Tezspire (tezepelumab) self-administration in a prefilled, single-use pen for patients 12 years of age and older for asthma.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period.

Based on Region, the global subcutaneous drug delivery market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Out of which, North America is expected to dominate the global subcutaneous drug delivery market over the forecast period, owing to increasing usage of auto injector and prefilled syringes in the market.

Global Subcutaneous Drug Delivery Market Cross Sectional Analysis:

Due to the increasing number of products being launched for epilepsy, the auto injector holds a dominant position in the delivery system segment in North America. For instance, in August 2022, according rafa laboratories, a pharmaceutical company, announced received approval from the FDA to launch a 10-mg midazolam autoinjector for the treatment of status epilepticus in adults.

Global Subcutaneous Drug Delivery Market: Key Developments

On January 13, 2023, MTD Group announced the FDA clearance obtained by its affiliate Pikdare S.p.A. for DropSafe Sicura passive safety needle with a completely passive mechanism that can be used to inject vaccines and other drugs into the muscle and under the skin.

In October 2022, scPharmaceuticals, a pharmaceutical company, announced the FDA approval for Furoscix (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure.

Global Subcutaneous Drug Delivery Market- Key Trends

Increasing the inorganic strategy of development and collaboration by major key players to boost the subcutaniouse drug dilevery market.

In November 2022, Kindeva Drug Delivery, Its capabilities include formulation, product development, scale-up manufacturing, and commercial manufacturing company is merging with ex-Pfizer subsidiary Meridian Medical Technologies to create a globetrotting drug-device contract development and manufacturing organization.

Global Subcutaneous Drug Delivery Market: Restraint

Increasing the number of product recalls from FDA

One factor impeding the growth of the worldwide subcutaneous medication delivery market is the lack of approved goods due to an increase in product recalls by different companies. Due to an increase in consumer complaints, the product has been discovered to be discoloured. For instance, on January 9, 2023, Spectrum Laboratory Products, Inc. a chemical manufacturing company, announced U.S.FDA gives alerts recall for EpiPen JR Auto-Injector, a bulk active epinephrine pharmaceutical ingredient (API) used to manufacture or compound prescription products.

Global Subcutaneous Drug Delivery Market: Key Players 

Major market players include Becton Dickinson and Company., Novo Nordisk A/S, Johnson & Johnson, Novartis International AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG., Consort Medical plc, LaVision Biotec GmbH, Eli Lilly and Company, Merck & Co., Inc, Insulet Corporation., West Pharmaceutical Services, Inc. Gerresheimer AG.

*Definition: A subcutaneous injection is a method of administering medication. Subcutaneous is the Latin word for skin. The tissue layer between the skin and the muscle is the target of this kind of injection, which uses a short needle. When administered this way, medication is typically absorbed over a longer length of time than when it is injected into a vein, sometimes up to 24 hours. When other administration techniques may not be as efficient, this kind of injection is performed. For instance, certain drugs cannot be administered orally because the stomach's acid and enzymes would destroy them.

Technological innovations and developments in prefilled syringes and auto-injectors is contributing to the market growth. For instance, Gerresheimer, German manufacturer of primary packaging introduced metal-free Lure Lock Gx RTF Syringe in June 2020, without tungsten to create the perfect primary packaging material for biotechnologically manufactured active ingredients that ideally exclude the possibility of contamination with metal.

Moreover, in March 2022, YpsoMed, medical device companies developed YpsoMate SmartPilot, a reusable attachment to its proprietary YpsoMate pen, which is designed for an easy two-step injection process. The device has a sensor and memory, which is connected to an app, which displays injection timing and doses. The pen provides audio and visual feedback to users. The app can also remind users when it is time to inject the insulin.

Market Dynamics

Product approvals by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on March 6, 2023, Coherus BioSciences, Inc, its global biosimilar company, announced U.S. Food and Drug Administration (FDA) approved a single-dose, prefilled auto injector presentation of UDENYCA (pegfilgrastim-cbqv). The UDENYCA autoinjector has a streamlined, easy-to-use design for use in both in-office and at-home settings of care.

Key features of the study:

  • This report provides in-depth analysis of the global subcutaneous drug delivery market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global subcutaneous drug delivery market based on the following parameters–company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Inc., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, Merck & Co., Inc., Insulet Corporation, West Pharmaceutical Services, Inc Gerresheimer AG and other prominent key players.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • Global subcutaneous drug delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global subcutaneous drug delivery market

Detailed Segmentation:

  • Global Subcutaneous Drug Delivery Market, Usability
    • Disposable
    • Reusable
  • Global Subcutaneous Drug Delivery Market, Disease Indication
    • Auto-immune Disorders
    • Neurological Disorders
    • Oncology Disorders
    • Hormonal Disorders
    • Allergy & Infectious Disorders
    • Ophthalmic Disorders
    • Others
  • Global Subcutaneous Drug Delivery Market, Delivery System
    • Prefilled Syringes
    • Autoinjector
      • Spring Type
      • Motorized Type
      • Wearable Type
    • Pen Injectors
      • Disposable
      • Reusable
      • Syringes (Injector)
    • Others (pump, etc.)
  • Global Subcutaneous Drug Delivery Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Subcutaneous Drug Delivery Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Becton Dickinson and Company,
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novo Nordisk A/S,
    • Johnson & Johnson
    • Novartis International AG
    • Amgen, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG.,
    • Consort Medical plc,
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Insulet Corporation,
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global Subcutaneous Drug Delivery Market is estimated to be valued at US$ 11.88 billion in 2023 and is expected to exhibit a CAGR of 9.7% between 2023 and 2030.    
Increasing product approval by key market players is expected to drive the market growth.
Auto-injector is the leading component in the market.
Recall of the product such as EpiPen JR Auto-Injector (Epinephrine USP).This factor are hinder the market.
Key companies covered as a part of this study include Becton Dickinson and Company., Novo Nordisk A/S, Johnson & Johnson, Novartis International AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG., Consort Medical plc, LaVision Biotec GmbH, Eli Lilly and Company., Merck & Co., Inc, Insulet Corporation., West Pharmaceutical Services, Inc. Gerresheimer AG. 

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo